Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. MDxHealth SA
  6. News
  7. Summary
    MDXH   BE0003844611

MDXHEALTH SA

(MDXH)
  Report
Real-time Euronext Bruxelles  -  03:00 2022-11-28 am EST
0.6850 EUR   -0.44%
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 2nd

02/17/2022 | 04:00pm EST

NEWS RELEASE
17 February 2022, 4:00 PM EST / 22:00 CET

MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results
and Corporate Update on March 2nd

Company to Host Conference Call with Live Q&A, March 2, 2022 at 4:30pm ET/ 22:30 CET

IRVINE, CA, and HERSTAL, BELGIUMFebruary 17, 2022MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2021, after market close on Wednesday, March 2, 2022.

Title:

MDxHealth Presents Fourth Quarter and Full Year 2021 Financial Results and
Recent Corporate Update Conference Call and Webcast
Speakers:Michael K. McGarrity, Chief Executive Officer
Ron Kalfus, Chief Financial Officer
Date:Wednesday, March 2, 2022
Time:4:30pm ET/ 22:30 CET
Conference Call Dial-in Details:

International: 323-994-2093
Belgium: 0800 58228
The Netherlands: 0800 023 1436
United Kingdom: 0800 358 6377
US: 800-204-4369
Conference ID: 2329214



Webcast:Webcast Link - Click Here

https://mdxhealth.com/events-news

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About MDxHealth

MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

MDxHealth

info@mdxhealth.com

 
LifeSci Advisors (IR & PR)
US: +1 949 271 9223
ir@mdxhealth.com
 

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations, and the demand for our products; our ability to successfully and profitably market our products; the acceptance of our products and services by healthcare providers; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; and the amount and nature of competition for our products and services. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AS-MDx and MonitorMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.


Attachment

  • MDxHealth Press Release

© OMX, source GlobeNewswire - EU Press Releases

All news about MDXHEALTH SA
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
10/27MDxHealth SA Reaffirms Revenue Guidance for the Year 2022
CI
10/27MDxHealth SA Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
08/26MDXHEALTH SA : Half-year report
CO
08/25MDxHealth SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/25MDxHealth Reports Half Year 2022 Results
GL
More news
Analyst Recommendations on MDXHEALTH SA
More recommendations
Financials
Sales 2022 40,9 M 42,5 M 42,5 M
Net income 2022 -33,9 M -35,3 M -35,3 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 112 M 117 M 117 M
Capi. / Sales 2022 2,74x
Capi. / Sales 2023 1,65x
Nbr of Employees 191
Free-Float 84,3%
Chart MDXHEALTH SA
Duration : Period :
MDxHealth SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MDXHEALTH SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,69
Average target price
Spread / Average Target -
Managers and Directors
Michael K. McGarrity Chief Executive Officer & Executive Director
Ron Kalfus Chief Financial Officer
Koen Hoffman Chairman
Miriam Reyes Executive Vice President-Operations
Joseph Sollee Chief Compliance Officer, EVP & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MDXHEALTH SA-22.00%117
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918